Related Experiment Video

Updated: May 31, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α

B Huang1, Z Qu, C W Ong

  • 1Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA.

Oncogene
|June 28, 2011
PubMed

Insights

RUNX3 acts as a tumor suppressor in breast cancer by reducing estrogen receptor alpha (ERα) stability. Loss of RUNX3 promotes ductal carcinoma and cancer cell proliferation, highlighting its critical role in breast cancer suppression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Transcription factor RUNX3 is implicated as a tumor suppressor in various cancers, including breast cancer.
  • The precise mechanism by which RUNX3 suppresses tumors in breast cancer is not fully understood.

Purpose of the Study:

  • To elucidate the tumor suppressor function of RUNX3 in breast cancer.
  • To investigate the molecular mechanisms underlying RUNX3's role in breast cancer, particularly its interaction with estrogen receptor alpha (ERα).

Main Methods:

  • Analysis of spontaneous ductal carcinoma development in Runx3(+/-) mice.
  • In vitro studies assessing RUNX3's effect on ERα-positive MCF-7 breast cancer cell proliferation, transformation, and tumorigenicity in vivo.
  • Investigation of RUNX3's impact on ERα stability and transactivation.
  • Correlation analysis of RUNX3 and ERα expression in various breast cancer models and human tissues.

Main Results:

  • Approximately 20% of female Runx3(+/-) mice developed spontaneous ductal carcinoma.
  • RUNX3 inhibited estrogen-dependent proliferation and transformation of ERα-positive MCF-7 cells and suppressed their tumorigenicity in mice.
  • RUNX3 reduced ERα stability, thereby inhibiting ERα-dependent transactivation.
  • Inverse correlation observed between RUNX3 and ERα expression in breast cancer cell lines, human tissues, and mouse tumors.

Conclusions:

  • RUNX3 functions as a novel tumor suppressor in breast cancer by destabilizing ERα.
  • RUNX3's tumor suppressor activity is linked to its regulation of ERα levels and activity.
  • Understanding RUNX3-ERα interaction provides insights into breast cancer pathogenesis and potential therapeutic strategies.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...